Related Experiment Video

Updated: May 2, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

564

Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant

Neha Singh1, Frank Jacobs1, Daniel J Rader2

  • 1Centre for Molecular and Vascular Biology, Department of Cardiovascular Sciences, Catholic University of Leuven, Leuven, Belgium.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|March 18, 2014
PubMed

Insights

High-density lipoprotein (HDL) function is impaired in heart transplant recipients, despite similar HDL cholesterol levels. This reduced HDL function is not linked to cardiac allograft vasculopathy (CAV).

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Science

Background:

  • High-density lipoprotein (HDL) metabolism is altered in heart transplant recipients.
  • HDL function may be impaired in these patients, impacting cardiovascular health post-transplant.

Purpose of the Study:

  • To investigate HDL function in heart transplant recipients.
  • To assess cholesterol efflux capacity and vasculoprotective function of HDL.
  • To determine the relationship between HDL function and cardiac allograft vasculopathy (CAV).

Main Methods:

  • Cross-sectional study of 52 heart transplant recipients 5-15 years post-transplantation.
  • Analysis of cholesterol efflux capacity using apolipoprotein B-depleted plasma.
  • Evaluation of HDL vasculoprotective function via endothelial progenitor cell migration assay.

Main Results:

  • Heart transplant recipients showed reduced normalized cholesterol efflux (24.1%) and vasculoprotective function (27.0%) compared to controls.
  • HDL function was similar in patients with and without CAV and not related to C-reactive protein (CRP) levels.
  • Higher CRP levels (≥6 mg/liter) were observed in patients with CAV.

Conclusions:

  • HDL function is impaired in heart transplant recipients.
  • Impaired HDL function is unrelated to CAV status in these patients.
  • CAV-positive patients have a higher proportion of elevated CRP levels.
Abstract

Keywords:
HDL functioncardiac allograft vasculopathycholesterol effluxendothelial progenitor cellheart transplantation

More Related Videos

Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.4K
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

8.1K

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382